Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Common Equity (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Common Equity for 16 consecutive years, with $540.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 33.95% to $540.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $540.7 million through Dec 2025, up 33.95% year-over-year, with the annual reading at $540.7 million for FY2025, 33.95% up from the prior year.
  • Common Equity hit $540.7 million in Q4 2025 for Ani Pharmaceuticals, up from $505.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $540.7 million in Q4 2025 to a low of -$92.6 million in Q3 2022.
  • Historically, Common Equity has averaged $190.5 million across 5 years, with a median of $101.8 million in 2021.
  • Biggest five-year swings in Common Equity: tumbled 864400.0% in 2023 and later soared 25290750.0% in 2025.
  • Year by year, Common Equity stood at -$3.1 million in 2021, then surged by 498.3% to $12.2 million in 2022, then crashed by 182.85% to -$10.1 million in 2023, then soared by 4104.36% to $403.7 million in 2024, then skyrocketed by 33.95% to $540.7 million in 2025.
  • Business Quant data shows Common Equity for ANIP at $540.7 million in Q4 2025, $505.8 million in Q3 2025, and -$31.6 million in Q2 2025.